Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

Randomized, double-blind, placebo-controlled trial of polyphenon E in prostate cancer patients before prostatectomy: evaluation of potential chemopreventive activities.

Nguyen MM, Ahmann FR, Nagle RB, Hsu CH, Tangrea JA, Parnes HL, Sokoloff MH, Gretzer MB, Chow HH.

Cancer Prev Res (Phila). 2012 Feb;5(2):290-8. doi: 10.1158/1940-6207.CAPR-11-0306. Epub 2011 Nov 1.

2.

The laminin binding integrin alpha6beta1 in prostate cancer perineural invasion.

Sroka IC, Anderson TA, McDaniel KM, Nagle RB, Gretzer MB, Cress AE.

J Cell Physiol. 2010 Aug;224(2):283-8. doi: 10.1002/jcp.22149. Review.

3.

SELDI protein profiling of dunning R-3327 derived cell lines: identification of molecular markers of prostate cancer progression.

Malik G, Rojahn E, Ward MD, Gretzer MB, Partin AW, Semmes OJ, Veltri RW.

Prostate. 2007 Oct 1;67(14):1565-75.

PMID:
17705230
5.

Modern Tumor Marker Discovery in Urology: Surface Enhanced Laser Desorption and Ionization (SELDI).

Gretzer MB, Partin AW, Chan DW, Veltri RW.

Rev Urol. 2003 Spring;5(2):81-9.

6.

54-year-old male with high-grade prostatic intraepithelial neoplasia on prostate biopsy.

Gretzer MB, Partin AW.

Rev Urol. 2003 Winter;5(1):45-8. No abstract available.

7.

Proteomic analysis of dunning prostate cancer cell lines with variable metastatic potential using SELDI-TOF.

Gretzer MB, Chan DW, van Rootselaar CL, Rosenzweig JM, Dalrymple S, Mangold LA, Partin AW, Veltri RW.

Prostate. 2004 Sep 1;60(4):325-31.

PMID:
15264244
8.

PSA markers in prostate cancer detection.

Gretzer MB, Partin AW.

Urol Clin North Am. 2003 Nov;30(4):677-86. Review.

PMID:
14680307
9.

Substratification of stage T1C prostate cancer based on the probability of biochemical recurrence.

Gretzer MB, Epstein JI, Pound CR, Walsh PC, Partin AW.

Urology. 2002 Dec;60(6):1034-9.

PMID:
12475665
10.

A critical analysis of the interpretation of biochemical failure in surgically treated patients using the American Society for Therapeutic Radiation and Oncology criteria.

Gretzer MB, Trock BJ, Han M, Walsh PC.

J Urol. 2002 Oct;168(4 Pt 1):1419-22. Erratum in: J Urol 2002 Dec;168(6):2558.

PMID:
12352408
11.

Development of F-18-labeled fluoroerythronitroimidazole as a PET agent for imaging tumor hypoxia.

Yang DJ, Wallace S, Cherif A, Li C, Gretzer MB, Kim EE, Podoloff DA.

Radiology. 1995 Mar;194(3):795-800.

PMID:
7862981
12.

Diagnostic and therapeutic potential of poly(benzyl L-glutamate).

Yang DJ, Li C, Nikiforow S, Gretzer MB, Kuang LR, Lopez MS, Vargas K, Wallace S.

J Pharm Sci. 1994 Mar;83(3):328-31.

PMID:
7515964

Supplemental Content

Loading ...
Support Center